ECCMID 25th (2015)

Title Content type
An open-label phase 3 study of Isavuconazole (VITAL): focus on patients with mixed fungal infections (click for details)
Drug interaction profiles of Isavuconazole, voriconazole and posaconazole with immunosuppressants metabolized by CYP4503A4 (CYP3A4) – (click for details)
A comparison of the safety profiles of Isavuconazole vs voriconazole in the phase 3 SECURE study in patients with invasive mould infections – (click for details)
Successful treatment of contaminated epidural steroid associated fungal meningitis with Isavuconazole (click for details)
Safety and outcomes in obese patients with invasive fungal disease treated with Isavuconazole in the phase 3 randomised double-blind SECURE trial – (click for details)
Safety and outcomes in invasive aspergillosis patients with renal vs. no renal impairment treated with Isavuconazole: experience from the SECURE (randomized) and VITAL trials (click for details)
Outcome of invasive aspergillosis after allogeneic haematopoietic stemcell transplantation in patientswith invasive aspergillosis before transplantation (click for details)
Fibrosis as a complication of chronic pulmonary aspergillosis (click for details)
Exposure response analysis of isavuconazole in patients with disease caused by Aspergillus species or other filamentous fungi (click for details)
Clinical outcomes by minimum inhibitory concentrations of baseline Aspergillus pathogens from isavuconazole phase 3 SECURE and VITAL studies (click for details)


Subscribe to ECCMID 25th (2015)